CardioKinetix Obtains $44,000,000 Series E Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    925 Hamilton Avenue Menlo Park, CA 94025
  • Company Description
    CardioKinetix, Inc. is developing new technology for treating Congestive Heart Failure (CHF). This is a catheter-based intervention implanted into the heart. CHF results from damage to the heart from several causes, which affects nearly five million people in the U.S.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series E
  • Proceeds Purposes
    This financing provides CardioKinetix the capital necessary to substantially progress the development of our PARACHUTE™ device, including conducting clinical studies to further support the initial commercialization of Parachute in Europe and a PMA submission to FDA.
  • M&A Terms
  • Venture Investor
    SV Life Sciences
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    U.S. Venture Partners
  • Venture Investor
    JPMorgan Partners
  • Venture Investor